FDA Class III Recall: JB Chemicals' Cetirizine Hydrochloride Tablets Affected by Imprinting Error
JB Chemicals and Pharmaceuticals Ltd has initiated a Class III recall of 13,440 bottles of Cetirizine Hydrochloride Tablets USP 10 mg due to incorrect tablet imprinting. Distributed U.S. nationwide by Rising Pharma Holdings, Inc., this event highlights critical quality control gaps at the Mumbai, India manufacturing facility, impacting supply chain integrity and demanding immediate action from procurement and regulatory teams.
FDA Class III Recall: Cetirizine Hydrochloride Tablets Imprinting Error Details
JB Chemicals and Pharmaceuticals Ltd, through its manufacturing division Unique Pharmaceuticals Labs in Mumbai, India, has initiated a voluntary Class III recall for specific lots of Cetirizine Hydrochloride Tablets USP 10 mg. This recall, identified as D-0033-2026, impacts 13,440 bottles of the 500-tablet presentation (NDC 16571-402-50), distributed U.S. nationwide by Rising Pharma Holdings, Inc. The core issue, as cited by the FDA, is that the 'Tablet/Capsules Imprinted with Wrong ID.' Affected lots include PY925014 and PY925013, both with an expiration date of January 31, 2028. While a Class III classification indicates a remote probability of serious adverse health consequences, this event carries significant operational and compliance implications for all stakeholders. For procurement directors, this means immediate action is required to identify and quarantine any inventory from the specified lots of Cetirizine Hydrochloride 10 mg. The disruption to the supply of this common over-the-counter (OTC) antihistamine, particularly in the 500-count bottle size, necessitates a rapid assessment of alternative sourcing strategies to maintain continuity for pharmacies and healthcare providers. Regulatory affairs heads must ensure that internal procedures for handling Class III recalls are meticulously followed, from initial firm notification via letter on September 12, 2025, through to complete resolution, to mitigate potential regulatory scrutiny and uphold market access for ANDA077829.
Supply Chain Exposure: Rising Pharma Holdings and U.S. Market Impact
The U.S. nationwide distribution of the recalled Cetirizine Hydrochloride Tablets USP 10 mg by Rising Pharma Holdings, Inc. places a substantial burden on their supply chain and downstream partners. With 13,440 bottles of a staple OTC medication affected, supply chain VPs at wholesalers, pharmacies, and retail chains must prioritize the identification, segregation, and return of these mislabeled products. This logistical undertaking involves significant resource allocation, from warehouse operations to customer service communications, all while ensuring minimal disruption to patient access for this essential allergy relief medication. Business development executives should recognize that such recalls, even if Class III, can erode brand confidence and create opportunities for competitors. Distributors like Rising Pharma Holdings, Inc. are compelled to review their supplier qualification processes and enhance their incoming quality inspection protocols to prevent similar incidents. The broad distribution pattern, encompassing NDCs such as 16571-402-10, 16571-402-30, and 16571-402-50, underscores the pervasive reach of this issue and the critical need for robust traceability systems throughout the pharmaceutical supply chain. This event serves as a stark reminder that even seemingly minor labeling discrepancies can trigger widespread market interventions, demanding agile and effective recall management strategies.
Manufacturing Quality Control Deficiencies at Unique Pharmaceuticals Labs, India
This recall event directly implicates the manufacturing quality control systems at Unique Pharmaceuticals Labs, a division of JB Chemicals and Pharmaceuticals Ltd, located in Mumbai, India. The fundamental error of 'Tablet/Capsules Imprinted with Wrong ID' suggests a lapse in critical Good Manufacturing Practices (GMP) related to product identification and labeling. Such an issue could stem from inadequate line clearance procedures, insufficient in-process quality checks, or a failure in the overall quality management system designed to prevent mix-ups and mislabeling. For global procurement directors and regulatory affairs heads sourcing active pharmaceutical ingredients (APIs) or finished dosage forms from India, this incident reinforces the imperative for rigorous supplier audits and ongoing performance monitoring. It is crucial to verify that manufacturing partners have robust controls in place for every stage of production, particularly those involving critical product identification attributes. This event underscores the need for comprehensive quality agreements that clearly define responsibilities and expectations for label control and imprinting accuracy. Business development executives considering partnerships with manufacturers in this region should factor in heightened scrutiny of quality assurance protocols to mitigate future compliance risks and safeguard product integrity in the U.S. market.
Navigating Class III Recall Remediation and Future Compliance Expectations
The 'Ongoing' status of this Class III recall means that JB Chemicals and Pharmaceuticals Ltd and Rising Pharma Holdings, Inc. are actively engaged in remediation efforts. While the Class III classification implies a low risk of serious health consequences, the FDA still expects a thorough and timely execution of the recall process. Regulatory affairs teams must ensure complete accountability for all recalled units, comprehensive root cause analysis for the imprinting error, and implementation of corrective and preventive actions (CAPAs) to prevent recurrence. This includes meticulous documentation of all communications, product retrievals, and destruction or relabeling activities. For business development executives, maintaining a pristine regulatory record is crucial for market access and partner trust, especially in the highly competitive generic drug sector. This event serves as a reminder that even voluntary, Class III recalls can impact a company's standing and necessitate significant investment in compliance infrastructure. Procurement directors should evaluate their risk assessment frameworks to include detailed scenarios for managing various recall classifications, ensuring that their supply chain partners, particularly those involved in manufacturing and distribution, possess equally robust and transparent recall management capabilities. Proactive engagement with regulatory bodies and transparent communication are paramount to navigating such events successfully and minimizing long-term commercial repercussions.